Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytrx Cp (CYTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 72,419
  • Shares Outstanding, K 118,720
  • Annual Sales, $ 200 K
  • Annual Income, $ -50,770 K
  • 36-Month Beta 1.22
  • Price/Sales 298.59
  • Price/Cash Flow 0.00
  • Price/Book 2.52
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.70
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/10/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.25 on 03/07/08
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.38 +60.53%
on 03/22/17
0.62 -1.61%
on 04/21/17
+0.20 (+48.78%)
since 03/21/17
3-Month
0.38 +60.53%
on 03/22/17
0.62 -1.61%
on 04/21/17
+0.19 (+45.24%)
since 01/20/17
52-Week
0.36 +69.44%
on 12/28/16
3.66 -83.33%
on 04/25/16
-2.64 (-81.23%)
since 04/21/16

Most Recent Stories

More News
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up

CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for...

HSKA : 105.17 (+0.42%)
GALE : 0.58 (unch)
LLY : 81.89 (-0.06%)
CYTR : 0.61 (+22.00%)
Blog Coverage CytRx Announces FDA's Approval for New Drug Application

Upcoming AWS Coverage on Alexion Pharmaceuticals Post-Earnings Results

CYTR : 0.61 (+22.00%)
ALXN : 116.82 (-1.60%)
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) today announced the U.S. Food and Drug Administration (FDA) has reached an agreement with CytRx on preparations for a New Drug Application (NDA) submission for aldoxorubicin...

CYTR : 0.61 (+22.00%)
CytRx Reports 2016 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the year ended December 31, 2016, and provided an...

CYTR : 0.61 (+22.00%)
CytRx to Present at the 29th Annual ROTH Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President...

CYTR : 0.61 (+22.00%)
Technical Reports on Biotech Stocks -- Halozyme Therapeutics, CytRx, Cara Therapeutics, and Keryx Biopharma

In today's pre-market research, Stock-Callers.com presents these Biotech equities for review: Halozyme Therapeutics Inc. (NASDAQ: HALO), CytRx Corp. (NASDAQ: CYTR), Cara Therapeutics Inc. (NASDAQ: CARA),...

CARA : 16.53 (-3.28%)
KERX : 5.69 (-2.90%)
CYTR : 0.61 (+22.00%)
HALO : 13.28 (+0.30%)
CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that,...

CYTR : 0.61 (+22.00%)
Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock?

Options traders are pricing in a big move for CytRx Corp (CYTR) shares as it has huge implied volatility

CYTR : 0.61 (+22.00%)
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer

CytRx Corporation (NASDAQ:CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel Levitt,...

CYTR : 0.61 (+22.00%)
CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into securities purchase agreements with existing institutional...

CYTR : 0.61 (+22.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

See More

Support & Resistance

2nd Resistance Point 0.68
1st Resistance Point 0.65
Last Price 0.61
1st Support Level 0.55
2nd Support Level 0.48

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.